Bibliografia UJ CM

1/3
Philipp Bernhard Staber, Wojciech Jurczak, Richard Greil, Vladan Vucinic, Jan Moritz Middeke, Marco Montillo, Talha Munir, Peter Neumeister, Johannes Schetelig, Stephan Stilgenbauer, Frank Striebel, Maren Dirnberger-Hertweck, Johannes Weirather, Wolfram Brugger, Peter Kelemen, Clemens-Martin Wendtner, Jennifer Ann Woyach.
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
Leukemia & Lymphoma
2021 : Vol. 62, nr 14, s. 3440-3451, il., bibliogr. 32 poz., abstr.
Autor korespondencyjny: Philipp Bernhard Staber.
Both authors contributed equally as first authors: Philipp Bernhard Staber and Wojciech Jurczak.
p-ISSN: 1042-8194
e-ISSN: 1029-2403
AZ
ORG
AIF
IF: 2.996
Adres url:
Streszczenie w PubMed:
2/3
Marco Montillo, Arpad Illes, Tadeusz Robak, Alexander S. Pristupa, Malgorzata Wach, Miklos Egyed, Julio Delgado, Wojciech Jurczak, Franck Morschhauser, Anan Schuh, Herebrt Eradat, Sanatan Shreay, Jacqueline C. Barrientos, Andrew D. Zelenetz.
Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients : results of a phase 3, randomized, controlled trial.
Health and Quality of Life Outcomes
2019 : Vol. 17, 173, il., bibliogr. 38 poz., abstr.
Open Access Creative Commons Attribution License CC-BY 4.0.
Autor korespondencyjny: Marco Montillo.
p-ISSN: 1477-7525
AZ
ORG
AIF
IF: 2.344
Adres url:
Streszczenie w PubMed:
3/3
Andrew D. Zelenetz, Jacqueline C. Barrientos, Jennifer R. Brown, Bertrand Coiffier, Julio Delgado, Miklós Egyed, Paolo Ghia, Árpad Illes, Wojciech Jurczak, Paula Marlton, Marco Montillo, Franck Morschhauser, Alexander S. Pristupa, Tadeusz Robak, Jeff P. Sharman, David Simpson, Lukas Smolej, Eugen Tausch, Adeboye H. Adewoye, Lyndah K. Dreiling, Yeonhee Kim, Stephan Stilgenbauer, Peter Hillmen.
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet. Oncology
2017 : Vol. 18, nr 3, s. 297-311, il., bibliogr. 22 poz., sum.
Autor korespondencyjny: Andrew D. Zelenetz.
p-ISSN: 1470-2045
AZ
ORG
AIF
IF: 36.418
Adres url:
Streszczenie w PubMed:
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ